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BACKGROUND: The procedure for allocating patients to a treatment arm in comparative clinical trials is frequently chosen with only
minor deliberation. This decision may, however, ultimately impact the trial inference, credibility, and even validity of the trial analysis.
Cancer researchers are increasingly using dynamic allocation (DA) procedures, which balance treatment arms across baseline
prognostic factors for clinical trials in place of historical methods such as simple randomisation or allocation via the random permuted
blocks.
METHODS: This article gives an overview of DA methods, the statistical controversy that surrounds these procedures, and the potential
impact on a clinical trial results.
RESULTS: Simple examples are provided to illustrate the use of DA methods and the inferential mistakes, notably on the P-value,
if incorrect analyses are performed.
INTERPRETATION: The decision about which method to use for allocating patients should be given as much consideration as other
aspects of a clinical trial. Appropriately choosing between methods can affect the statistical tests required and what inferences are
possible, while affecting the trial credibility. Knowledge of the different methods is key to appropriate decision-making.
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Randomised clinical trials have long been considered the gold
standard in clinical research (Concato et al, 2000). Strictly
speaking, a randomised clinical trial is one where the allocation
of patients to treatment arm occurs according to a random
mechanism. In practice, this is typically performed using some sort
of computer-generated list or random number generator. The
allocation procedure is termed simple random sampling (Zelen,
1974) and gives every patient the exact same chance of being
allocated to receive each treatment. The use of a random
mechanism is the cornerstone of these trials and is the basis for
statistical theory and analysis of these trials (Greenland, 1990).
However, not all clinical trials use a strict randomisation
procedure to allocate patients. Dynamic allocation (DA) methods
(Pocock and Simon, 1975), which balance prognostic factors
between treatment groups, often referred to as minimisation
(Taves, 1974), are a primarily deterministic, non-random algo-
rithm being implemented with increasing regularity by cancer
researchers in clinical trials (Pond et al, 2010). The effect on
clinical trial interpretation when using these methods is not
necessarily trivial, and has caused substantial debate regarding
their usefulness and validity (Senn, 2000). Some authors argue that
for clinical trials, ‘if randomisation is the gold standard,
minimisation may be the platinum standard’ (Treasure and
MacRae, 1998). Other authors have claimed these techniques are
not necessary, possibly even detrimental, and use of these methods
should be ‘strongly discouraged’ (Committee for Proprietary
Medicinal Products, 2003; Senn, 2004).
While this controversy appears to be well discussed in the
statistical literature (Rosenberger and Lachin, 2002; Buyse and
McEntegart, 2004a; Roes, 2004; Taves, 2004; Day et al, 2005;
Senn et al, 2010), anecdotally it appears less appreciated in the
clinical cancer research literature. Further, and possibly of greater
concern, is there may be an underappreciation of the effect of non-
randomised allocation on results, including the P-value, when
using standard statistical analyses. Therefore, this manuscript was
written with an aim to inform investigators who plan to
incorporate DA methods in their clinical trials of some of the
strengths and limitations of these techniques.
WHAT IS DYNAMIC ALLOCATION?
Randomisation permits an unbiased comparison between patients
allocated to different treatments (Altman and Bland, 1999). Use of
randomisation ensures asymptotic balancing of patients to
treatment, and of baseline prognostic factors, including factors
that are unknown at the time of randomisation. That is, the
number of patients allocated to each treatment arm will approach
equality, and prognostic factors will be equally balanced within
patients across different treatments, in a clinical trial as the sample
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ssize increases infinitely. For any given trial, which has a finite
sample size, however, there may be an imbalance between
treatment arms in one, or more, known or unknown prognostic
factors. Standard statistical theory is able to objectively quantify
the possibility of an imbalance and even correct or adjust results
for imbalances when they do occur (Lachin, 1988). However,
performing statistical adjustments for imbalanced prognostic
factors are not recommended if the adjustment was not initially
planned as this can lead to questions of multiple testing (Pocock
et al, 1987). Even when adjusting for an imbalanced prognostic
factor is planned initially, a clinical trial having an imbalance,
especially a large one, can be very concerning and possibly even
detrimentally affect the credibility of the trial (Buyse and
McEntegart, 2004b). Methods that reduce the possibility of a trial
having a large imbalance between treatment arms for a known
prognostic factor have therefore been proposed. Taves (1974)
proposed an algorithm called minimisation, which is a determi-
nistic method to allocate patients to treatment. The following year,
Pocock and Simon (1975) independently presented a more general
family of algorithms, called DA methods of which minimisation is
one specific approach. Although earlier reviews indicated these
methods were used very infrequently (Altman and Dore, 1990; Lee
and Feng, 2005), a recent cancer-specific review of multi-arm
clinical trials indicated their use is increasing and no longer
uncommon (Pond et al, 2010).
To illustrate how DA methods work, let us consider a
hypothetical two-arm clinical trial in breast cancer where three
patient baseline covariates are considered prognostic: Her2-neu
status (positive or negative), menopausal status (post-menopausal
or pre-/peri-menopausal), and stage of disease (II or III). Assume
the breakdown by treatment of the baseline prognostic factors for
the first 19 patients is summarised in Table 1 and the 20th patient,
a post-menopausal, Her2-neu-negative patient with stage II
disease, is ready to be enrolled in the trial.
Using Taves minimisation algorithm, or equivalently the Pocock–
Simon range method with allocation probability of 1, the number of
previously enrolled patients with the same prognostic factor as the
new patient is counted. The new patient would then be allocated to
the treatment arm for which the sum of the previously enrolled
patient prognostic factor counts is smallest. That is, if the 20th patient
was allocated to treatment A, then there would be 5þ1H e r 2 - n e u -
negative patients, 6þ1 post-menopausal patients, and 7þ1s t a g eI I
patients assigned to treatment A, which is summed to be
(5þ1)þ(6þ1)þ(7þ1)¼21. Alternatively, if the 20th patient was
allocated to treatment B, a total sum of (3þ1)þ(4þ1)þ
(2þ1)¼12 is obtained. Since 12o21, the patient would be assigned
to treatment B, minimising the imbalance.
Many authors have proposed, and continue to propose,
modifications to these algorithms (Wei, 1977; Begg and Iglewicz,
1990; Heritier et al, 2005; Perry et al, 2010). While some of these
methods may modestly increase efficiency, most are rarely used.
One modification that does appear to be utilised regularly is to add
in a random component; thus, allocation is no longer completely
deterministic. For example, in the hypothetical trial above, patient
20 would be allocated to treatment B with probability P, 0.5oPo1.
A probability of P¼0.8 has been shown to be most efficient
(Brown et al, 2005).
OTHER COMMON ALLOCATION METHODS
Simple random sampling is the most basic allocation method
(Zelen, 1974). Each patient is assigned with equal probability to
different treatment arms, regardless of all other considerations.
Generally performed in practice by creating a randomisation list
based on a random number table, or a computerised random
number generator, it is equivalent to the notion of allocating
patients by flipping a fair coin.
Another frequently used method is allocation via the random
permuted blocks (Zelen, 1974). Also known as block randomisa-
tion, stratified random sampling, or permuted block sampling, the
patient allocation list is grouped into blocks of size 2k (assuming
1:1 allocation) with k patients in each block assigned to each
treatment. For example, if the block size is set to 4, then there are
six ways, or permutations, in which two patients can be allocated
to each treatment within a given block: AABB, ABAB, ABBA,
BAAB, BABA, and BBAA. For each block, a permutation is selected
at random and patients are assigned to treatment as they are
enrolled according to that permutation. When that block is full,
another permutation is selected for the next group of patients.
A separate list of permuted blocks is created for each combination
of strata. In the illustrative example, there would be 2 2 2¼8
lists created, one for each combination of Her2-neu status,
menopausal status, and disease stage. Although not well under-
stood, allocation via the random permuted blocks method is not an
entirely random technique. The last patient allocated within each
block is completely determined by the allocation of the previous
patients within that block. To reduce potential selection bias, a
simple modification is to vary the block size throughout the trial.
Another dynamic procedure is a biased coin method (Efron,
1971). Using this method, a patient is randomly allocated to the
treatment arm which has fewer patients already accrued with
probability P, where 0.5oPo1. If there is no difference in the
number of patients treated in each arm, the next patient has an
equal probability of being assigned to each treatment. An adaptive
biased coin design (Hofmeijer et al, 2008) is one where the value of
P for each patient allocation depends on the degree of imbalance in
the number of patients previously enrolled to each arm.
Alternatively, one could perform simple random sampling as long
as the imbalance in the number of patients previously enrolled to
each arm overall, or within a centre or some other prognostic
factor, is less than some value m, but switching to a biased coin
design when the imbalance is m or larger.
Response-adaptive allocation is another DA method (Zelen,
1969; Zhou et al, 2008). Patients are allocated to treatment as in a
biased coin design, that is, allocated to one treatment arm with
probability P, however, the value of P is determined based on the
outcomes of patients previously enrolled in the study. If a
treatment effect is observed, the value of P changes to allow
patients a better opportunity of receiving the treatment with the
best results. Over the course of the trial, this allocation method
aims to optimise patient outcomes and more patients will receive
the superior treatment.
CONSIDERATIONS WHEN SELECTING AN
ALLOCATION METHOD
A number of points should be considered when selecting an
allocation method for use in a particular trial. For example, trials
implementing DA methods must have sufficient statistical and
programming support available to prevent avoidable algorithm
and programming errors. An accessible and reliable centralised
database is required for investigators to register patients and to
perform the treatment allocation. Depending on the trial, this
database may need to be coordinated with centre pharmacies or
companies shipping treatment to the study centre. While this
support is likely available within most large, cooperative groups,
Table 1 Summary of baseline prognostic factors for first 19 patients on
hypothetical trial
Treatment A Treatment B
Number of patients 10 9
Her2-neu status Positive:Negative 5:5 6:3
Menopausal status Pre-/peri–post-:4 : 6 5 : 4
Stage II:III 7:3 2:7
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sit may be less accessible in smaller centres or companies doing
only a limited number of clinical trials. The cost and time required
to develop these systems may not be feasible or viable given the
small savings in sample size afforded by a balanced trial (Senn,
2004). Alternatively, for very expensive novel therapies, a small
savings in sample size could be financially advantageous,
particularly if many of the systems are already in place. One
might additionally consider potential imbalances in costs between
individual study centres if discrepancies were to occur in the
number of patients receiving each treatment at different sites. This
might occur when there are differences in supportive care costs or
in the number of follow-up visits – especially if a costly imaging
procedure is included at each follow-up – between treatment arms.
Scientifically, the number and importance of known prognostic
factors should factor in the decision of which allocation method to
use. If the number and effect on the outcome of prognostic factors
is large relative to the total trial sample size, preventing an
imbalance might be of greater concern than a trial with few
prognostic factors, which has only a modest effect on the outcome
and a large sample size. The selection of method to use might be
affected if some prognostic factors have a greater effect on
outcome than others. Alternatively, one might be concerned with
and choose an allocation algorithm based on the issue of selection
bias, which might arise in an open-label trial or when the
comparison treatments are extremely dissimilar (e.g., surgery vs
non-surgical therapies). Selection bias arises when investigators
can guess with improved probability the treatment future patients
will be assigned to receive. Although concerning for deterministic
algorithms when physicians know the characteristics of previous
patients enrolled, the ability to guess assignment for future
patients becomes negligible when centre is not used in the
algorithm scheme or a random probability is included in the
algorithm (Brown et al, 2005).
Finally, one must think about the ultimate analysis and
conclusions that might be inferred from a particular trial. Is it
likely a sceptic will discount a result if an imbalance is present? Do
investigators have sufficient statistical support to address any
potential inferential concerns if they are raised? If the trial is being
conducted in preparation for a regulatory submission, have the
authorities provided any guidance? As recently as 2003, the
Committee for Proprietary Medicinal Products noted that DA
methods remained highly controversial and strongly advised
against their use (Committee for Proprietary Medicinal Products,
2003). Their concern is driven by logistical and practical flaws in
previous applications using DA methods, and due to theoretical
concerns (Day et al, 2005). Although one certainly does not want to
use DA methods which could prove problematic if there is no
perceived benefit (Day et al, 2005), the logistical and practical
concerns can be addressed with proper algorithmic testing and
attention (Buyse and McEntegart, 2004a). Of greater issue is the
theoretical concerns which results from the fact that standard
statistical analysis techniques are based on random allocation
methods and DA methodology is not random. The distribution of
possible outcomes depends on the allocation method used.
Consequently, P-values obtained using tests which assume random
allocation will not be correct when a DA algorithm was used. To
illustrate the extent of this potential problem, an example is
provided in the next section.
ILLUSTRATIVE EXAMPLE
Assume eight patients are allocated as part of a clinical trial to one
of two treatment arms, as illustrated in Table 2. For simplicity, let
the rank order of the patient outcomes be listed and one-sided
tests were performed to better illustrate the P-value calculations.
Two-sided P-values could be calculated by doubling the one-sided
P-value.
Initially, assume one has no knowledge of the prognostic factor
status for each patient. At the analysis stage, it is then known that
patients 1, 4, 7, and 8 were allocated to treatment arm A, and these
patients had the first, sixth, second, and fifth best treatment
outcomes. When an incorrect statistical test is applied to these
results, the reported P-value might be greatly affected. For
example, if an investigator ignored that the data were rank order
data and assumed the underlying distribution of the data was
normal, one might consider using the Welch’s two-sample t-test,
which gives a one-sided P-value of 0.1399. An underlying
assumption here is that patients in this trial are randomly sampled
from the population at large. This assumption may not be true for
clinical trials (Ranstam, 2009), although it is often overlooked
when allocation of patients to treatment arm is a random process.
More appropriately, one might use a permutation test which is not
based on the assumption of randomisation. This test proceeds
as follows: there are 8
4

¼ 70 possible ways of selecting four of
the eight patients to receive treatment A. The sum of the ranks of
those patients who received treatment A is 14 (1þ2þ5þ6). Of
the 70 total permutations, there are 12 for which the sum of ranks
is 14 or less; that is, would give as strong, or stronger, evidence in
favour of a treatment effect for treatment A. This is the basis for
calculating a Wilcoxon’s rank-sum test, and gives a one-sided
P-value of 12/70¼0.1714.
Additional information is available given that we know the
prognostic factor status of all eight patients. A classical
randomisation-based analysis might be to use linear regression,
adjusting for the prognostic factor if, similar to the t-test, an
investigator ignored that the data were rank order data and
assumed the underlying distribution of the data was normal. In
this case, the one-sided P-value is 0.0033. To do a permutation test,
one starts with the four prognostic factor-positive patients and
calculating the six ways in which these four patients can be
allocated such that two patients receive treatment A and two
receive treatment B (AABB, ABAB, ABBA, BBAA, BABA, and
BAAB). This is similar to using a permuted block allocation
method with block size of 4. Of the factor-positive patients, the
observed outcome is the most extreme outcome in favour of
treatment arm A, since the two patients allocated to arm A
(patients 1 and 7) had better outcomes than the two patients
allocated to arm B (patients 6 and 3). Therefore, the probability of
this (for prognostic factor-positive patients) is 1/6. Similarly, of the
factor-negative patients, the two patients allocated to arm A
(patients 4 and 8) had better outcomes than the two patients
allocated to treatment B (patients 2 and 5). Overall, then, the
one-sided P-value is 1/6 1/6¼0.0278.
The P-value is different, however, had one used Taves’
deterministic minimisation procedure. Using this algorithm, there
are only four allocation possibilities for the factor-positive patients
and four possibilities for the factor-negative patients. This is
because it is impossible for the first two patients with identical
prognostic factor status both to be allocated to the same treatment
arm. Patient 1 is allocated to treatment arm A with probability 0.5
which means the next factor-positive patient (patient 3) is
Table 2 Hypothetical clinical trial
Order of patient
entry into study
Treatment
allocation
Prognostic
factor
Outcome
order
1A + 1
2B   8
3B + 4
4A   6
5B   7
6B + 3
7A + 2
8A   5
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imbalance. The next factor-positive patient (patient 6) is allocated
to treatment arm B with probability 0.5, therefore, the next factor-
positive patient (patient 7) must receive the opposite treatment
(A). Hence, there are only four allocation possibilities: ABAB,
ABBA, BABA, and BAAB.
In this situation, patients are paired. Patients 1 and 3 receive
opposite treatments, as do patients 6 and 7. Of factor-negative
patients, patients 2 and 4 receive opposite treatments, as do
patients 5 and 8. In all pairs of patients, the patient who received
treatment A did better than the patient who received treatment B.
There is no possible way of allocating patients using minimisation,
which would create a more extreme outcome favouring treatment
A. Then, the one-sided P-value is 1/4 1/4¼0.0625.
Finally, assume one used a biased coin method with P¼0.8.
There remain six possible ways of allocating two of four patients to
treatment arm A, within each prognostic factor stratum. However,
in this case, the probabilities are different for each possibility,
unlike the random permuted blocks method. To calculate the
P-value, one must calculate the probability of each scenario
occurring. The resulting one-sided P-value is 0.0434.
In summary, obtaining the correct P-value depends on using the
correct test for the allocation method which is used (see Table 3).
The difference in the P-value because of different allocation
methods can change the result from a ‘statistically significant at the
a¼0.05 level’ result to a non-statistically significant result.
DISCUSSION
Despite increasingly frequent implementation of DA methods
which aim to balance prognostic factors between treatment arms
(Pond et al, 2010), their use remains controversial (Senn, 2000).
Many of the early criticisms of these methods, that they are too
complex, might hinder investigators from performing clinical
trials, or that they require a centralised database which might be
practically difficult (Peto et al, 1976), are less consequential today
due to more powerful computers, instant communication, and
increasing awareness of the need for comparative clinical trials
(Schulz et al, 2010). Other criticisms remarking on programming
errors can be remedied through vigilance and repeated testing of
allocation programs by dedicated statistical and programming
teams. Finally, there are concerns that blinding can be compro-
mised when using these methods (Day et al, 2005). A number of
common strategies can be employed to reduce the possibility of
unblinding, such as adding a random component and not using
centre as a stratification factor (Brown et al, 2005). Importantly,
one should not reveal the allocation procedure to investigators
involved in enrolling patients and, whenever possible, blind them
to the treatment the patients actually receive.
The bigger inferential concern remains, that of using common,
but incorrect, statistical analyses which assume random allocation
of patients. The use of common statistical tests is in part due to the
wide recognition of these tests, but also because it is extremely
complex (if not impossible) to perform the correct permutation
test when sample sizes, and the number of stratification factors,
increase (Knijnenburg et al, 2009). One argument for the validity
of these tests is that the order of patient accrual can be considered
random, although this is not universally accepted (Simon, 1979).
Simulations have shown the impact of using random allocation
tests instead of permutation tests is small when sample sizes are
reasonably large and adjustment for prognostic factors is
performed (Birkett, 1985; Kalish and Begg, 1987; Tu et al, 2000);
thus, the use of standard tests should not be much of a concern
(McEntegart, 2003). It is further noted that use of statistical tests
which assume random allocation are frequently applied when
using permuted block methods, another non-random procedure,
and there is little concern of the impact on these results.
While most authors advocate adjusting for covariates used as
stratification factors in the final analysis, the argument of
increased credibility of DA methods over simple random sampling
is related to the unadjusted, univariate model (Buyse and
McEntegart, 2004a). As the presented example shows there might
be substantial differences between the unadjusted and adjusted
analyses, and it is always important to investigate when there are
differences.
Numerous options are available to investigators conducting a
cancer clinical trial for treatment allocation between comparison
arms. Careful consideration should occur in the trial design phase
to select the method best suited for a given trial. This decision
could impact the inferential ability and credibility of a trial and
should not be perceived as trivial. Knowledge of the impact of the
allocation method on the trial is essential to proper understanding
of the results, regardless of procedure used.
In summary, DA should be considered a valid alternative to
randomisation or allocation via the random permuted blocks
method, particularly for small to moderate-sized clinical trials with
multiple significant prognostic factors having modest to large
treatment effects, as is common in oncology. While it is
recommended that only a few factors be used when using the
random permuted blocks method – as a rule of thumb, the total
number of cells should be less than n/2 – DA methods can handle
many factors without difficulty (Therneau, 1993). Even with DA
methods, however, it is advised that only factors with a known,
large prognostic effect be included and there should be at least five
patients per cell (Rovers et al, 2000). Using a balanced coin
algorithm and incorporating a random element with probability
P¼0.8 is most efficient for reducing the ability to predict future
patient allocations while maintaining good balance (Brown et al,
2005). While statistical tests based on the assumption of
randomisation may give similar results, the P-value will only be
precisely correct when using the statistical test corresponding to
the allocation algorithm used. At a minimum, investigators should
perform multivariable analyses which adjust for all factors used in
the DA algorithm and perform appropriate sensitivity analyses
(Committee for Proprietary Medicinal Products, 2003).
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